CELL AND GENE THERAPY INSIGHTS

October 2020 Issue

Volume 6 Issue 9

Cell and Gene Therapy Insights Volume 6 Issue 9
Download PDF

Featuring

Issue Spotlight: New horizons in cellular immunotherapy: next-gen platforms and modalities
Other articles
Webinars

SPOTLIGHT

New horizons in cellular immunotherapy: next-gen platforms and modalities
David Morrow
Guest Editor:
David Morrow, Scientific Programme Manager, Translational Medicine & Drug Development at EATRIS

Expert Insight

Temferon™, an ex-vivo genetically modified cell therapy aiming to fill the gaps for solid tumor immunotherapy

Temferon™, an ex-vivo genetically modified cell therapy aiming to fill the gaps for solid tumor immunotherapy

S Mazzoleni, B Gentner, V Brambilla et al.
13 November 2020
Read
Engineering precision cell therapy for immune-mediated disease

Engineering precision cell therapy for immune-mediated disease

Michael Milone, Gwendolyn Binder
27 October 2020
Read
Immunological tolerance: scanning a barren landscape for signs of sustained growth

Immunological tolerance: scanning a barren landscape for signs of sustained growth

Harry Petropoulos, Timothy Davies, Paul Fairchild
28 September 2020
Read

Innovator Insight

Evolving the role of gene editing in cell therapy

Evolving the role of gene editing in cell therapy

Jonathan Frampton, Torsten Meissner, Tristan Thwaites
29 October 2020
Read
Promising non-viral vector for efficient and versatile delivery of mRNA for antigen-specific immunotherapy

Promising non-viral vector for efficient and versatile delivery of mRNA for antigen-specific immunotherapy

R Firdessa-Fite, J Postigo-Fernandez, V Toussaint-Moreau et al.
29 October 2020
Read

Commentary

Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors

Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors

D Morrow, J Langermans, A Ussi et al.
20 October 2020
Read
Is a second wave of (CAR T) cell based cancer therapies a mirage or reality?

Is a second wave of (CAR T) cell based cancer therapies a mirage or reality?

David Gilham
22 September 2020
Read

Interview

Driving lupus out with CARs

Driving lupus out with CARs

Marko Radic
22 October 2020
Read

Regulatory Insight

FDA perspective on the preclinical development of cell-based immunotherapies

FDA perspective on the preclinical development of cell-based immunotherapies

Alyssa Kosmides Galaro, Christopher Saeui
23 October 2020
Read

Journal articles

Editorial

Leading the way in bringing gene therapy to the CNS with conditioning: a renaissance for busulfan?

Leading the way in bringing gene therapy to the CNS with conditioning: a renaissance for busulfan?

Chris Mason
22 October 2020
Read

Expert Insight

Process development and scale-up of pluripotent stem cell manufacturing

Process development and scale-up of pluripotent stem cell manufacturing

S Huang, A Razvi, Z Anderson-Jenkins et al.
22 October 2020
Read

Commentary

Major clinical stories and read-outs from key conferences for the cell and gene therapy space

Major clinical stories and read-outs from key conferences for the cell and gene therapy space

Sven Kili
25 November 2020
Read
Boldly de-risking development of impactful cell and gene therapies: the California Stem Cell Agency’s $3B funding model

Boldly de-risking development of impactful cell and gene therapies: the California Stem Cell Agency’s $3B funding model

Shyam Patel, Sohel Talib, Maria Millan
5 October 2020
Read

Interview

Driving disruptive innovation in the ATMP field

Driving disruptive innovation in the ATMP field

Kerstin Papenfuss
6 October 2020
Read

Webinars